drugset / Trial / NCT02259803

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

NCT02259803

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative bioavailability of fixed-dose combination tablet vs. mono-components of telmisartan and amlodipine

Timeline

Start
2007-10
Primary completion
2007-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Telmisartan Other / unclassified 40 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral

Indications

No indication recorded.